AbbVie Reports Phase 3 Data on Ombitasvir-Paritaprevir-Ritonavir Therapy for Hepatitis C in Japan
Hepatitis C, News
AbbVie announced findings from a Phase 3 clinical trial (GIFT-I (M13-004)) for its new oral, ribavirin (RBV)-free antiviral treatment with a fixed-dose combination of paritaprevir/ritonavir (150/100 mg) with ombitasvir (25 mg), ... Read more